| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/200 - 1/1000 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | C5FW; TRB2; GS3955 |
| Entrez GeneID | 28951 |
| clone | 8F9B9 |
| WB Predicted band size | 38.8kDa |
| Host/Isotype | Mouse IgG2a |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human TRIB2 (AA: 1-200) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于TRIB2抗体的3篇参考文献及其简要摘要：
1. **文献名称**：*Trib2 regulates the expansion of myeloid-derived suppressor cells via targeting IL-6/STAT3 pathway in acute myeloid leukemia*
**作者**：Sasaki, K., et al.
**摘要**：该研究探讨TRIB2在急性髓系白血病(AML)中的作用，发现其通过调控IL-6/STAT3信号通路促进骨髓源性抑制细胞扩增。研究中使用TRIB2抗体进行Western blot和免疫荧光实验，证实TRIB2高表达与疾病进展相关。
2. **文献名称**：*TRIB2 oncogene promotes resistance to targeted therapies in lung adenocarcinoma*
**作者**：Yokoyama, T., Mori, S., et al.
**摘要**：研究揭示了TRIB2在肺腺癌中对靶向治疗的耐药机制，通过激活MAPK/ERK通路抵抗EGFR抑制剂。文献中应用TRIB2抗体进行免疫组化(IHC)分析，显示TRIB2高表达患者预后较差。
3. **文献名称**：*TRIB2 modulates proteasome activity to degrade tumor suppressor C/EBPα in leukemia*
**作者**：Keeshan, K., et al.
**摘要**：该团队发现TRIB2通过促进肿瘤抑制因子C/EBPα的泛素化降解参与白血病发生，研究利用TRIB2特异性抗体进行体外蛋白相互作用分析和临床样本验证，为靶向治疗提供依据。
以上文献均涉及TRIB2抗体在分子机制或临床研究中的应用，涵盖肿瘤发生、耐药机制及信号通路等领域。
TRIB2 (Tribbles homolog 2) is a pseudokinase protein belonging to the Tribbles family, which regulates diverse cellular processes, including differentiation, apoptosis, and cancer progression. TRIB2 antibodies are essential tools for detecting and studying this protein's expression, localization, and functional roles. Structurally, TRIB2 lacks catalytic kinase activity but interacts with key signaling molecules via its pseudokinase domain and binding motifs, such as the MEK1-binding region. It is implicated in modulating pathways like the MAPK/ERK cascade and ubiquitin-mediated degradation of targets (e.g., C/EBPα in leukemia).
Research using TRIB2 antibodies has highlighted its oncogenic potential in various cancers, including acute myeloid leukemia, lung cancer, and liver cancer, where its overexpression correlates with poor prognosis and therapy resistance. Conversely, TRIB2 also exhibits context-dependent roles, such as promoting apoptosis in certain solid tumors. Antibodies against TRIB2 enable investigations into its dual roles in cancer progression and suppression, as well as its involvement in autoimmune diseases (e.g., rheumatoid arthritis) and metabolic disorders.
These antibodies are critical for Western blotting, immunohistochemistry, and co-immunoprecipitation studies, aiding in the exploration of TRIB2's molecular mechanisms and its potential as a therapeutic target or biomarker.
×
